Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
GNTA Genenta Science
6.140+0.340+5.86%
Trading Session
01/31 11:08 ET
High
6.140
Open
6.000
Turnover
6.60K
Low
5.950
Pre Close
5.800
Volume
1.10K
Intraday
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
We Think Genenta Science (NASDAQ:GNTA) Can Easily Afford To Drive Business Growth
Genenta Science (NASDAQ:GNTA) Research Coverage Started at EF Hutton Acquisition Co. I
EF Hutton Acquisition Co. I began coverage on shares of Genenta Science (NASDAQ:GNTA – Get Rating) in a research note released on Thursday morning, Benzinga reports. The brokerage issued a buy rating
Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2023
UpgradesFor Algonquin Power & Utilities Corp (NYSE:AQN), Wells Fargo upgraded the previous rating of Equal-Weight to Overweight. In the third quarter, Algonquin Power showed an EPS of $0.11, compared
Genenta Science Price Target Announced at $15.00/Share by EF Hutton
Genenta Science Price Target Announced at $15.00/Share by EF Hutton
Genenta Science Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 01/05/2023 168.82% EF Hutton → $15 Initiates Coverage On → Buy 07/25/2022 348.03% HC Wainwright & Co. → $2
EF Hutton Initiates Coverage On Genenta Science With Buy Rating, Announces Price Target of $15
EF Hutton analyst Tony Butler initiates coverage on Genenta Science (NASDAQ:GNTA) with a Buy rating and announces Price Target of $15.
Genenta Science Initiated With a Buy at EF Hutton
Critical Review: Immunocore (NASDAQ:IMCR) Versus Genenta Science (NASDAQ:GNTA)
Genenta Science (NASDAQ:GNTA – Get Rating) and Immunocore (NASDAQ:IMCR – Get Rating) are both medical companies, but which is the superior investment? We will compare the two companies based on the s
Analyzing Genenta Science (NASDAQ:GNTA) & Immunocore (NASDAQ:IMCR)
Genenta Science (NASDAQ:GNTA – Get Rating) and Immunocore (NASDAQ:IMCR – Get Rating) are both medical companies, but which is the superior stock? We will contrast the two companies based on the stren
Genenta Science S.p.A. (NASDAQ:GNTA) Sees Significant Decrease in Short Interest
Genenta Science S.p.A. (NASDAQ:GNTA – Get Rating) was the target of a large decline in short interest in November. As of November 30th, there was short interest totalling 500 shares, a decline of 80
Company Overview
More
Genenta Science SpA is a clinical-stage biotechnology company, which engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors. Its lead product candidate, Temferon, was developed using its platform and carries an interferon-alpha payload. The company was founded by Pierluigi Paracchi, Luigi Naldini and Bernhard Gentner on July 24, 2014 and is headquartered in Milan, Italy.
CEO： Mr. Pierluigi Paracchi
Market： NASDAQ
Listing Date： 12/15/2021
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet